Shares of Biocon soared over 4 percent on January 13 after the US Food and Drug Administration cleared arm Biocon Biologics' insulin facility in Malaysia, putting an end to a major regulatory ...

Shares of Biocon Ltd surged as much as 5 per cent during the trading session on Monday after the United States Food and Drug Administration (USFDA) cleared the Malaysia unit, ending regulatory ...

HSBC highlighted several factors that could drive earnings growth, including the FDA’s recent clearance of Biocon’s Malaysia plant, which addresses prior concerns regarding Good Manufacturing ...

for the insulin facility of Biocon Biologics in Malaysia. This development marks the resolution of a significant regulatory bottleneck for the company. After the Malaysian unit was designated as a ...

KUALA LUMPUR, Jan 7 (Bernama) -- Biocon Biologics is committed to implementing business expansion in Malaysia. Biocon Biologics is a global company with capabilities in the development, manufacturing ...

we believe Biocon is improving its execution, which is reflected in its market share gain for launched products. The FDA clearance for its Malaysia insulin plant on 12 January 2025 culminated its ...

With the Bengaluru unit getting a go ahead from the FDA, regulatory clearance for Biocon's Malaysia unit remains the focal points for investors. Aside from the regulatory clearance, Jefferies ...

Biocon Ltd’s share price fell 4.86 per cent on January 27, 2025, hitting a day’s low of Rs 369.40 on the NSE, while the NIFTY ...

classified Biocon Biologics' insulin facilities in Johor Bahru, Malaysia, as Voluntary Action Indicated (VAI). “This relates to the cGMP inspection conducted by the agency between September 15–27, ...

The upgrade reflects a turnaround driven by biosimilar launches, improved generics sales, and US FDA clearance of Biocon’s Malaysia plant. HSBC's new target price represents a 48.3% increase, ...